I would think in that case there will be a rush to approval for those solid tumors with the highest response to Kevetrin and possibly (probably?) even approval for use under Phase 4.
Could you clarify this? In general, Phase 3 is the study to support a FDA approval application and Phase 4 refers to any continued study on risks and benefits, while being marketed as approved.